Total Valuation
Bio View has a market cap or net worth of ₪11.37M. The enterprise value is 11.95M.
Market Cap₪11.37M
Enterprise Value11.95M
Share Statistics
Bio View has 13,898,633 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,898,633
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bio View’s return on equity (ROE) is -1.63 and return on invested capital (ROIC) is -62.01%.
Return on Equity (ROE)-1.63
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-62.01%
Return on Capital Employed (ROCE)-0.69
Revenue Per Employee642.90K
Profits Per Employee-494.58K
Employee Count31
Asset Turnover1.00
Inventory Turnover1.84
Valuation Ratios
The current PE Ratio of Bio View is ―. Bio View’s PEG ratio is -0.00380.
PE Ratio―
PS Ratio1.14
PB Ratio2.41
Price to Fair Value2.41
Price to FCF-7.28
Price to Operating Cash Flow-3.81
PEG Ratio-0.00380
Income Statement
In the last 12 months, Bio View had revenue of 19.93M and earned -15.33M in profits. Earnings per share was -1.10.
Revenue19.93M
Gross Profit8.75M
Operating Income-7.80M
Pretax Income-9.15M
Net Income-15.33M
EBITDA-7.19M
Earnings Per Share (EPS)-1.10
Cash Flow
In the last 12 months, operating cash flow was -3.06M and capital expenditures -53.00K, giving a free cash flow of -3.11M billion.
Operating Cash Flow-3.06M
Free Cash Flow-3.11M
Free Cash Flow per Share-0.22
Dividends & Yields
Bio View pays an annual dividend of 200, resulting in a dividend yield of ―
Dividend Per Share200
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change-65.51%
50-Day Moving Average103.80
200-Day Moving Average148.80
Relative Strength Index (RSI)38.73
Average Volume (3m)133.91K
Important Dates
Bio View upcoming earnings date is Nov 18, 2021, TBA (Confirmed).
Last Earnings DateAug 19, 2021
Next Earnings DateNov 18, 2021
Ex-Dividend Date―
Financial Position
Bio View as a current ratio of 1.88, with Debt / Equity ratio of 29.67%
Current Ratio1.88
Quick Ratio1.17
Debt to Market Cap0.06
Net Debt to EBITDA0.30
Interest Coverage Ratio-33.63
Taxes
In the past 12 months, Bio View has paid 6.18M in taxes.
Income Tax6.18M
Effective Tax Rate-0.68
Enterprise Valuation
Bio View EV to EBITDA ratio is -2.86, with an EV/FCF ratio of -6.60.
EV to Sales1.03
EV to EBITDA-2.86
EV to Free Cash Flow-6.60
EV to Operating Cash Flow-6.71
Balance Sheet
Bio View has ₪7.22M in cash and marketable securities with ₪2.79M in debt, giving a net cash position of ₪4.43M billion.
Cash & Marketable Securities₪7.22M
Total Debt₪2.79M
Net Cash₪4.43M
Net Cash Per Share₪0.32
Tangible Book Value Per Share₪0.69
Margins
Gross margin is 47.76%, with operating margin of -39.15%, and net profit margin of -76.93%.
Gross Margin47.76%
Operating Margin-39.15%
Pretax Margin-45.90%
Net Profit Margin-76.93%
EBITDA Margin-36.06%
EBIT Margin-45.30%
Analyst Forecast
The average price target for Bio View is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-22.32%
EPS Growth Forecast-355.07%